Guerrero BJ, Graue HEO

Language: Spanish
References: 12
Page: 275-279
PDF size: 244.02 Kb.

ABSTRACT

Dry eye syndrome is a very common cause of ophthalmological consultation, it is a condition characterized by high tear osmolarity, tear film instability and ocular surface inflammation. The main etiologies are age, feminine gender, meibomian gland dysfunction, contact lens use, environmental factors and systemic drugs. The main mechanisms that cause dry eye are reduction in tear production, alteration of the corneal nerves or a direct toxicity to the lacrimal gland. Many drugs are related to dry eye syndrome, this are important in daily medical practice due to the frequent use. Some of the group of drugs that have been related to dry eye syndrome are: NSAIDs (nonsteroidal anti-inflammatory drugs), gastric protector drugs, antihypertensive agents, anxiolytics, oral contraceptives, antidepressants, antipsychotics, antihistamines and drugs for treating Parkinson’s disease, among others. The purpose of this review is to briefly summarize the most common systemic medications and the possible mechanism related to dry eye disease.

REFERENCES

1. Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK et al. TFOS DEWS II report executive summary. Ocul Surf. 2017; 15 (4): 802-812.

2. Askeroglu U, Alleyne B, Guyuron B. Pharmaceutical and herbal products that may contribute to dry eyes. Plast Reconstr Surg. 2013; 131: 159-167.

3. Clayton JA. Dry eye. N Engl J Med. 2018; 378 (23): 2212-2223.

4. Burke JP. Book Review Preventing Medication Errors (Quality Chasm Series.) By the Committee on Identifying and Preventing Medication Errors and the Board on Health Care Services. Edited by Philip Aspden, Julie A. Wolcott, J. Lyle Bootman, and Linda R. Cronenwett. 463 pp. Washington, DC, National Academies Press, 2007. 54.95. 978-0-309-10147-9 Medication Errors Second edition. Edited by Michael R. Cohen. 680 pp., illustrated. Washington, DC, American Pharmacists Association, 2007. 89.95. 978-1-58212-092-8. N Engl J Med. 2007; 357: 624-625. doi: 10.1056/NEJMbkrev58255.

5. Blomquist PH. Ocular complications of systemic medications. Am J Med Sci. 2011; 342 (1): 62-69. doi: 10.1097/MAJ.0b013e3181f06b21.

6. Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15: 511–538.

7. Wong J, Lan W, Ong LM, Tong L. Non-hormonal systemic medications and dry eye. Ocul Surf. 2011; 9 (4): 212-226.

8. Marino D, Malandrini A, Rocchi R, Selvi E, Federico A. Transient "sicca syndrome" during phenobarbital treatment. J Neurol Sci. 2011;300: 164.

9. Lamberts DW, Foster CS, Perry HD. Schirmer test after topical anesthesia and the tear meniscus height in normal eyes. Arch Ophthalmol. 1979; 97 (6): 1082-1085.

10. Ikäheimo K, Kettunen R, Mäntyjärvi M. Visual functions and adverse ocular effects in patients with amiodarone medication. Acta Ophthalmol Scand. 2002; 80 (1): 59-63.

11. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993; 328 (4): 246-252.

12. Logan JL, Ahmed J. Critical hypokalemic renal tubular acidosis due to Sjögren’s syndrome: association with the purported immune stimulant echinacea. Clin Rheumatol. 2003; 22 (2): 158-1589. doi: 10.1007/s10067-002-0671-4.

EVIDENCE LEVEL

III